![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
X
20
Mitrychem S.a.s. Mitry-mory Fr, based in France, is a pharmaceutical company.
One of their significant offerings is Olanzapine, supported by a 'Expired' Certificate of Suitability (CEP) with the number R0-CEP 2012-402 - Rev 00
This Chemical Type CEP, issued on January 23, 2015, remains in force until January 23, 2020, ensuring its reliability within the pharmaceutical industry.
Substance Number 2258 associated with this CEP further emphasizes